1. The metabolic fate of a new antitumour agent, 1-hexylcarbamoyl-5-fluoro[6-14C]uracil (14C-HCFU) was compared with that of 5-fluoro[6-14C]uracil (14C-FU) after oral administration to mice. 2. 1-(5-Hydroxyhexylcarbamoyl)-5-fluorouracil (5-hydroxy-HCFU) and 1-(5-oxohexylcarbamoyl)-5-fluorouracil (5-keto-HCFU) were found as major intermediate metabolites of 14C-HCFU and were produced by omega-1 oxidation. 3. FU was detected in plasma 180 min after oral administration of 14C-HCFU, whereas unchanged FU disappeared within 60 min after 14C-FU. 4. 14C-HCFU and resulting FU were retained in tissues for a long period after oral administration, while administered 14C-FU was rapidly degraded.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/00498258009033815 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The association between serum ferritin levels and the risk of gestational diabetes mellitus: a prospective cohort study.
BMC Pregnancy Childbirth
January 2025
Department of Central Laboratory, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, No.251 Yaojiayuan Road, Chaoyang District, Beijing, 100026, China.
Background: The relationship between serum ferritin levels and the risk of gestational diabetes mellitus (GDM) remains unclear. This study aimed to investigate the association between serum ferritin levels and the incidence of GDM.
Methods: We conducted a prospective cohort study involving 10,871 pregnant women from the China Birth Cohort Study.
Sodium-Glucose Co-Transporter 2 Inhibitors and Severe Urinary Tract Infections: Real-World Meta-Analysis of Cohort Studies.
Ann Pharmacother
January 2025
Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Objective: There is limited knowledge about severe urinary tract infections associated with SGLT2i, despite this being the basis for the Food and Drug Administration (FDA) warning. We aim to provide real-world evidence to clarify this relationship further.
Data Source: A literature review was performed in PubMed and Embase for cohort studies published up to August 2024 using PICO-consistent terms.
Characterization of human alcohol dehydrogenase 4 and aldehyde dehydrogenase 2 as enzymes involved in the formation of 5-carboxylpirfenidone, a major metabolite of pirfenidone.
Drug Metab Dispos
January 2025
Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kakuma-machi, Kanazawa, Japan; WPI Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, Kakuma-machi, Kanazawa, Japan.
Pirfenidone (PIR) is used in the treatment of idiopathic pulmonary fibrosis. After oral administration, it is metabolized by cytochrome P450 1A2 to 5-hydroxylpirfenidone (5-OH PIR) and further oxidized to 5-carboxylpirfenidone (5-COOH PIR), a major metabolite excreted in the urine (90% of the dose). This study aimed to identify enzymes that catalyze the formation of 5-COOH PIR from 5-OH PIR in the human liver.
View Article and Find Full Text PDFOrally-Administrable Supramolecular Probiotic Capsules Enable Cooperative Colon-Targeted Inflammation Inhibition for Ameliorating Ulcerative Colitis.
Acta Biomater
January 2025
School of Life Sciences, Chongqing University, Chongqing, 400044, China.. Electronic address:
Ulcerative colitis (UC) is a prevalent gastrointestinal disease characterized by the chronical and refractory inflammation of colorectal mucosa and walls, which severely impairs overall well-being of individuals. Probiotics has shown tremendous promise for UC therapy due to its multifaceted mucosal barrier restoration and immunomodulation capabilities. Nevertheless, the successful administration of probiotics remains a clinical obstacle.
View Article and Find Full Text PDFToxicological profile of Acovenoside A as an active pharmaceutical ingredient - prediction of missing key toxicological endpoints using in silico toxicology methodology.
Chem Biol Interact
January 2025
Safety Assessment, Syngene International Limited, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore, 560099, Karnataka, India.
Acovenoside A, a cardenolide glycoside from Acokanthera oppositifolia, demonstrates significant therapeutic potential in cardioprotection and oncology, particularly against non-small cell lung cancer (NSCLC). However, its toxicological profile requires thorough evaluation for safe pharmaceutical application. For this purpose a comprehensive in silico methods were applied, including ACD/Labs Percepta, STopTox, admetSAR 3.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!